These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 26130368)

  • 1. Enhancing efficiency and quality of statistical estimation of immunogenicity assay cut points through standardization and automation.
    Su C; Zhou L; Hu Z; Weng W; Subramani J; Tadkod V; Hamilton K; Bautista A; Wu Y; Chirmule N; Zhong ZD
    J Immunol Methods; 2015 Oct; 425():88-96. PubMed ID: 26130368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An immunoinhibition approach to overcome the impact of pre-existing antibodies on cut point establishment for immunogenicity assessment of moxetumomab pasudotox.
    Schneider AK; Vainshtein I; Roskos LK; Chavez C; Sun B; Liang M
    J Immunol Methods; 2016 Aug; 435():68-76. PubMed ID: 27220271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elucidation of the statistical factors that influence anti-drug antibody cut point setting through a multi-laboratory study.
    Nishimura K; Shibata H; Aoyama M; Hosogi J; Kadotsuji K; Minoura K; Mori T; Nakamura T; Nishimiya K; Nomura T; Saito T; Soma M; Wakabayashi H; Sakamoto N; Niimi S; Katori N; Saito Y; Ishii-Watabe A
    Bioanalysis; 2019 Mar; 11(6):509-524. PubMed ID: 30945932
    [No Abstract]   [Full Text] [Related]  

  • 4. Recommendations for Systematic Statistical Computation of Immunogenicity Cut Points.
    Devanarayan V; Smith WC; Brunelle RL; Seger ME; Krug K; Bowsher RR
    AAPS J; 2017 Sep; 19(5):1487-1498. PubMed ID: 28733862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A formal comparison of different methods for establishing cut points to distinguish positive and negative samples in immunoassays.
    Jaki T; Lawo JP; Wolfsegger MJ; Singer J; Allacher P; Horling F
    J Pharm Biomed Anal; 2011 Jul; 55(5):1148-56. PubMed ID: 21561734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statistical considerations for calculation of immunogenicity screening assay cut points.
    Hoffman D; Berger M
    J Immunol Methods; 2011 Oct; 373(1-2):200-8. PubMed ID: 21906599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-normal random effects models for immunogenicity assay cut point determination.
    Zhang J; Yu B; Zhang L; Roskos L; Richman L; Yang H
    J Biopharm Stat; 2015; 25(2):295-306. PubMed ID: 25356500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics.
    Gorovits B; Wakshull E; Pillutla R; Xu Y; Manning MS; Goyal J
    J Immunol Methods; 2014 Jun; 408():1-12. PubMed ID: 24861938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statistical approaches for the determination of cut points in anti-drug antibody bioassays.
    Schaarschmidt F; Hofmann M; Jaki T; Grün B; Hothorn LA
    J Immunol Methods; 2015 Mar; 418():84-100. PubMed ID: 25733352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity assay development and validation for biological therapy as exemplified by ustekinumab.
    Mojtahed Poor S; Ulshöfer T; Gabriel LA; Henke M; Köhm M; Behrens F; Geisslinger G; Parnham MJ; Burkhardt H; Schiffmann S
    Clin Exp Immunol; 2019 May; 196(2):259-275. PubMed ID: 30656642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a novel capillary electrophoresis-based approach for detection of anti-drug antibody responses.
    Zhang S; Chen M; Zhou S; Raoufi F; Wiswell D; Hsieh S; Seghezzi W
    J Immunol Methods; 2021 Jul; 494():113047. PubMed ID: 33775673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-drug Antibody Assay Conditions Significantly Impact Assay Screen and Confirmatory Cut-Points.
    Gorovits B; Wang Y; Zhu L; Araya M; Kamerud J; Lepsy C
    AAPS J; 2019 Jun; 21(4):71. PubMed ID: 31161482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Approaches to Mitigate the Unwanted Immunogenicity of Therapeutic Proteins during Drug Development.
    Salazar-Fontana LI; Desai DD; Khan TA; Pillutla RC; Prior S; Ramakrishnan R; Schneider J; Joseph A
    AAPS J; 2017 Mar; 19(2):377-385. PubMed ID: 28083796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics.
    Gupta S; Indelicato SR; Jethwa V; Kawabata T; Kelley M; Mire-Sluis AR; Richards SM; Rup B; Shores E; Swanson SJ; Wakshull E
    J Immunol Methods; 2007 Apr; 321(1-2):1-18. PubMed ID: 17307199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statistical methods and tool for cut point analysis in immunogenicity assays.
    Zhang L; Zhang JJ; Kubiak RJ; Yang H
    J Immunol Methods; 2013 Mar; 389(1-2):79-87. PubMed ID: 23305975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A breakthrough novel method to resolve the drug and target interference problem in immunogenicity assays.
    Zoghbi J; Xu Y; Grabert R; Theobald V; Richards S
    J Immunol Methods; 2015 Nov; 426():62-9. PubMed ID: 26255760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of immunoassay for protein biomarkers: bioanalytical study plan implementation to support pre-clinical and clinical studies.
    Valentin MA; Ma S; Zhao A; Legay F; Avrameas A
    J Pharm Biomed Anal; 2011 Jul; 55(5):869-77. PubMed ID: 21530130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity assay cut point determination using nonparametric tolerance limit.
    Zhang J; Li W; Roskos LK; Yang H
    J Immunol Methods; 2017 Mar; 442():29-34. PubMed ID: 28063769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality control, analysis and secure sharing of Luminex® immunoassay data using the open source LabKey Server platform.
    Eckels J; Nathe C; Nelson EK; Shoemaker SG; Nostrand EV; Yates NL; Ashley VC; Harris LJ; Bollenbeck M; Fong Y; Tomaras GD; Piehler B
    BMC Bioinformatics; 2013 Apr; 14():145. PubMed ID: 23631706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of a generic immunoassay with drug tolerance to detect immune complexes in serum samples from cynomolgus monkeys after administration of human antibodies.
    Stubenrauch K; Wessels U; Essig U; Vogel R; Schleypen J
    J Pharm Biomed Anal; 2010 Jun; 52(2):249-54. PubMed ID: 20083366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.